IMPACT ON SEXUAL FUNCTION IN PATIENTS WITH DEPRESSIVE DISORDERS TREATED WITH ANTIDEPRESSANTS

• DOI: 10.22533/at.ed.1592762225112

• Palavras-chave: Sexual function; Antidepressant; Depression.

• Keywords: Sexual function; Antidepressant; Depression.

• Abstract:

  The relationship between depression, its treatment and sexual dysfunction is complex. Sexual dysfunction has a high comorbidity with depression. Some aspects of sexual function, especially libido, may improve with successful treatment. However, some psychotropic drugs used to treat psychological problems such as depression and anxiety can induce sexual dysfunction, especially delayed ejaculation. However, this review aims to highlight this process, as it subsidizes the development of more effective actions and treatments aimed at communities. In this context, the aim of this study was to compile the literature on the impact of sexual function in men with depression who use antidepressants, in order to elucidate risk factors and possible interventions. The survey of articles was carried out in the following databases: Medline/BVS and Medline/Pubmed. The following descriptors and their combinations in Portuguese and English were used to search for articles: “Antidepressants AND Sexual function AND Men AND Depression // Antidepressants AND Sexual function AND Men AND Depression”. This finding validates the study and confirms that a duration of 5 weeks is sufficient to observe differences in antidepressant-related changes in sexual function. References 1-3 demonstrate the association of antidepressant use with interfering with sexual function in men with depression or another psychiatric disorder. Only in article 4, it shows that there is no impact on sexual function between men who received the treatment with those who did not. This review corroborates that there is an impact on the sexual function of patients who use antidepressants to treat depressive disorder and generalized anxiety disorder. However, the drugs that had a direct influence on sexual dysfunction were paroxetine, fluoxetine and sertraline, although Trazodone and Mirtazapine were shown to be protective factors during the 6-month follow-up.